Key result
Asymmetric dimethylarginine (ADMA) is associated with the progression of chronic kidney disease, potentially through mechanisms involving glomerular filtration barrier compromise and renal fibrosis.
Design
Review
Authors
Loading...
ADMA may flag CKD progression risk; hypothesis-generating and should not yet change practice or prompt targeted therapy.
ADMA is highlighted as a significant marker for endothelial dysfunction and a potential mechanistic contributor to the progression of chronic kidney disease.
Raptis et al. (2012) conducted a review in Renal disease. Asymmetric dimethylarginine (ADMA) was evaluated on Progression of renal disease. Asymmetric dimethylarginine (ADMA) is associated with the progression of chronic kidney disease, potentially through mechanisms involving glomerular filtration barrier compromise and renal fibrosis.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: